HealthBeacon PLC HealthBeacon - HBCN - Directorate Change

Healthbeacon

16/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231016:nRSP1927Qa&default-theme=true

RNS Number : 1927Q  HealthBeacon PLC  16 October 2023

 

 

Directorate change - Non Executive Director

 

 

Dublin, 16 October 2023.  The board of HealthBeacon plc ("HealthBeacon" or
the "Company) announces that, Jim Joyce, Non-Executive Director, informed the
Board of his intention to step down from the Board Effective Friday 13(th)
October 2023.

 

 

 

 

-Ends-

 

 Enquiries:                                       Investor.Relations@HealthBeacon.com
                                                  (mailto:Investor.Relations@HealthBeacon.com)
 HealthBeacon:

 Rebecca Shanahan

 Lar Malone

 Goodbody (Euronext Listing Sponsor and Broker):  +353 (1) 667 0420

 Finbarr Griffin

 David Kearney

 Drury (Public Relations):
 Cathal Barry                                     +353 (0) 87 227 9281
 Gavin McLoughlin                                 +353 (0) 86 035 3749

 

About HealthBeacon

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company
that develops smart tools for managing medications for patients in the home.
The HealthBeacon Injection Care Management System tracks adherence and
persistence with medication schedules through the provision of medication
management reminders, safe and sustainable sharps disposal devices,
educational tools, and artificial intelligence (AI) driven data analytics.
Peer reviewed evidence supports a 19% improvement in therapy persistence by
patients and up to 26% improvement in adherence to therapy, which improves
clinical outcomes and significantly improves efficiency in health systems. The
Company has expanded its offering to growth management with the launch of its
integrated Smart Scale and oral adherence with the launch of HB Wave which
integrates with its existing technology. The Company operates across Europe,
North America and the United Kingdom and employs more than 70 people and has
obtained more than 30 design and utility patents. The Company's mission is to
become the world's leading digital therapeutics platform for patients managing
medications in the home.

End

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ISEFFFFFIDLELIV